人民财讯10月29日电，海正药业（600267）10月29日公告，公司及全资子公司瀚晖制药有限公司参加了 联合采购办公室组织的第十一批全国药品集中采购的投标工作。根据联采办于2025年10月28日在上海阳 光医药采购网发布的《全国药品集中采购拟中选结果公示》，公司及全资子公司瀚晖制药符合本次集中 采购范围的3个产品拟中标本次集中采购，分别为普伐他汀钠片、注射用丁二磺酸腺苷蛋氨酸、艾曲泊 帕乙醇胺片。 ...

每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 曾健辉） 2024年1至12月份，海正药业的营业收入构成为：医药生产占比58.46%，药品销售占比39.29%，其他行 业占比1.94%，其他业务占比0.23%，CMO/CDMO/CRO业务占比0.08%。 截至发稿，海正药业市值为132亿元。 每经AI快讯，海正药业（SH 600267，收盘价：11.03元）10月29日晚间发布公告称，近日，浙江海正药 业股份有限公司及全资子公司瀚晖制药有限公司参加了联合采购办公室组织的第十一批全国药品集中采 购的投标工作。根据联采办于2025年10月28日在上海阳光医药采购网发布的《全国药品集中采购拟中选 结果公示》，公司及全资子公司瀚晖制药符合本次集中采购范围的3个产品拟中标本次集中采购。普伐 他汀钠片，2025年1-6月销售收入5420万元。注射用丁二磺酸腺苷蛋氨酸，2025年1-6月销售收入8896万 元。艾曲泊帕乙醇胺片，2025年1-6月销售收入74万元。 ...

人民财讯10月28日电，普洛药业（000739）10月28日公告，近日，公司控股子公司浙江普洛康裕制药有 限公司参加了国家组织药品联合采购办公室组织的第十一批全国药品集中采购，公司产品注射用丁二磺 酸腺苷蛋氨酸拟中选本次集中采购。公司本次拟中选品种于2024年11月取得《药品注册证书》，视同通 过仿制药质量和疗效一致性评价。 ...

每经AI快讯，普洛药业（SZ 000739，收盘价：15.45元）10月28日晚间发布公告称，近日，普洛药业股 份有限公司控股子公司浙江普洛康裕制药有限公司参加了国家组织药品联合采购办公室组织的第十一批 全国药品集中采购，公司产品注射用丁二磺酸腺苷蛋氨酸拟中选本次集中采购。 2025年1至6月份，普洛药业的营业收入构成为：医药行业占比99.6%，其他业务占比0.4%。 截至发稿，普洛药业市值为179亿元。 每经头条（nbdtoutiao）——A股突破4000点！十年沉寂终迎爆发，科技主线重塑市场，"慢牛"新格局开 启！ （记者 曾健辉） ...

每经AI快讯，10月28日，普洛药业（000739）(000739.SZ)公告称，公司控股子公司浙江普洛康裕制药 有限公司参加了第十一批全国药品集中采购，公司产品注射用丁二磺酸腺苷蛋氨酸拟中选。该产品适用 于肝硬化前和肝硬化所致肝内胆汁淤积，以及妊娠期肝内胆汁淤积。若公司后续签订采购合同并实施， 将有利于扩大相关产品的销售规模，提高市场占有率，对公司未来经营业绩产生积极影响。但中选产品 相关采购合同尚未签订，后续事项存在不确定性。 ...

Group 1 - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a 5-year lifecycle, starting mass production in Q2 2026 [1] - Zhongke Environmental reported a net profit of 196 million yuan for the first half of 2025, a year-on-year increase of 19.83%, with revenue of 848 million yuan, up 4.48% [1] - WuXi AppTec's net profit for the first half of 2025 grew by 101.92% to 8.561 billion yuan, with revenue of 20.799 billion yuan, a 20.64% increase [1][2] - Sujiao Technology's net profit decreased by 39.54% to 95.39 million yuan, with revenue down 13.75% to 1.776 billion yuan [1] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5%, with revenue of 575 million yuan, up 11.69% [1] Group 2 - Sanxiang New Materials plans to invest up to 300 million yuan in a zirconium-hafnium separation project, with a production capacity of 20,000 tons [1] - Koweil received government subsidies totaling 4.9752 million yuan, accounting for 10.14% of its audited net profit [1] - Xinhua Medical obtained two Class II medical device registration certificates for digital X-ray machines [1] - Huanxu Electronics reported a net profit of 638 million yuan, down 18.66%, with total revenue of 27.214 billion yuan, a slight decrease of 0.63% [1] - Zhenhua Co.'s general manager was fined 100,000 yuan for violations related to stock trading by his child [1] Group 3 - Huafeng Aluminum signed a raw material purchase contract worth over 7.2 billion yuan for a five-year period, committing to purchase at least 360,000 tons of raw materials [1] - Hongxin Technology received a project designation letter and procurement contract from a major domestic automotive brand [1] - Meihe Co. obtained a patent for a device used in supporting automatic flipping on conveyor lines in the automotive manufacturing sector [1] - Xin Hongye's subsidiary won a bid for an electrical penetration project worth 40.8831 million yuan [1] - Fuan Pharmaceutical's subsidiary received a drug registration certificate for an injection used in liver disease treatment [1] Group 4 - Tianzhong Precision's subsidiary's bankruptcy liquidation application was accepted by the court due to insufficient assets to cover debts [1] - Zhonghong Medical's subsidiary received medical device registration for infusion pumps and information collection systems [1] - Keda Li's subsidiary completed a capital increase, raising its registered capital from 200 million yuan to 400 million yuan [1] - Xingye Technology applied for a credit limit of 372 million yuan from Guangfa Bank [1] - Hengrui Medicine signed a collaboration agreement with GSK, involving a potential total payment of approximately 12 billion USD based on project milestones [1]

Core Viewpoint - Fu'an Pharmaceutical (300194) announced that its wholly-owned subsidiary, Zhichu Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for an injectable drug, Adenosylmethionine Bisulfate, which is indicated for conditions related to liver cirrhosis and intrahepatic cholestasis during pregnancy [1] Group 1 - The drug is specified in a dosage of 0.5g and has the approval number H20254936 [1] - The acquisition of this drug registration certificate will enhance the product line of the subsidiary and improve its market competitiveness [1] - There are uncertainties regarding the production and sales of the product, as well as its specific impact on the company's performance, due to factors such as pharmaceutical policies and market environment changes [1]